News | Heart Valve Technology | December 14, 2022

Edwards Identifies Top Data Releases of 2022 that Highlight the Impacts of Aortic Stenosis Undertreatment

Edwards Lifesciences identified the top data releases from 2022 that contributed most to shaping awareness about the extent and impact of underdiagnosis and undertreatment of aortic stenosis (AS).

December 14, 2022 — Edwards Lifesciences identified the top data releases from 2022 that contributed most to shaping awareness about the extent and impact of underdiagnosis and undertreatment of aortic stenosis (AS). 

Commenting on the identified studies, Larry L. Wood, corporate vice president, transcatheter aortic valve replacement said, "The TAVR-focused data published this year, including these specific studies, brought important insights and helped shape the discussion on the extent and impact of the undertreatment of aortic stenosis in terms of health impacts to patients and costs to society." As a whole, the studies suggest substantial health and economic benefits are available through the wider use of transcatheter aortic valve replacement (TAVR). 

The highlighted studies are: 

"Trends in Utilization of Aortic Valve Replacement for Severe Aortic Stenosis," (Li, et al) published in the Journal of the American College of Cardiology (JACC) in March, found that less than half of the patients studied who had an indication or possible indication for aortic valve replacement (AVR) underwent the procedure. The untreated group experienced a significantly higher mortality rate than the patients undergoing AVR. 

In "Evolution and Prognostic Impact of Cardiac Damage After Aortic Valve Replacement," (Généreux, et al) published in the August edition of JACC, the findings suggest that earlier detection of aortic stenosis and intervention before development of irreversible cardiac damage may improve cardiac function and reduce mortality. 

An analysis entitled "Contemporary Costs Associated with Transcatheter Versus Surgical Aortic Valve Replacement in Medicare Beneficiaries," (Baron, et al) published in February in Circulation: Cardiovascular Interventions, found that in the year following treatment, TAVR saves between $10K and $29K per patient relative to surgical aortic valve replacement (SAVR) depending on the patient risk level. 

Finally, a study entitled "Cost-Utility and Cost-Benefit Analysis of TAVR Availability in the US Severe Symptomatic Aortic Stenosis Patient Population," (Sevilla, et al) published in the August issue of Journal of Medical Economics concluded that "across risk, age, and treatment-eligibility groups, TAVR is the economically optimal treatment choice. It represents strong value-for-money per patient and population-wide. The vast majority of TAVR value involves raising treatment uptake among the untreated." This analysis also quantified the productive contributions to society of the elderly symptomatic severe aortic stenosis patient when TAVR is available as a treatment option. 

Wood continued, "I believe there is a clear message in this body of evidence that swift diagnosis and treatment of aortic stenosis prevents cardiac damage, lowers mortality, and improves quality of life for these patients. These current studies also indicate that by taking a more comprehensive view of value and cost, there is a tremendous potential for savings to the healthcare system through the greater adoption of TAVR. Taken together, I think these studies really challenge the key stakeholders in the cardiovascular healthcare system to find and address the causes of the undertreatment of aortic stenosis." 

For more information: https://www.edwards.com/


Related Content

News | Endovascular Aortic Repair

June 19, 2024 — Stereotaxis, a pioneer and global leader in surgical robotics for minimally invasive endovascular ...

Home June 19, 2024
Home
News | Endovascular Aortic Repair

October 30, 2023 — -egnite, Inc., a leading cardiovascular digital health company, announced today that novel research ...

Home October 30, 2023
Home
News | Endovascular Aortic Repair

December 5, 2022 — Imagen Technologies, Inc. announced the U.S. Food and Drug Administration's 510(k) clearance of the ...

Home December 05, 2022
Home
News | Endovascular Aortic Repair

October 26, 2022 — Thousands of people have new hope for treatment of thoracic aortic arch disease and University ...

Home October 26, 2022
Home
News | Endovascular Aortic Repair

March 22, 2022 – A retrospective evaluation of 600 fenestrated-branched endovascular aortic repairs for the treatment of ...

Home March 22, 2022
Home
News | Endovascular Aortic Repair

February 18, 2022 – Front Line Medical Technologies, Inc. today announced the expanded availability and distribution of ...

Home February 18, 2022
Home
News | Endovascular Aortic Repair

May 12, 2021 — Preliminary results of a clinical trial, presented today at the AATS 101st Annual Meeting, showed that a ...

Home May 12, 2021
Home
News | Endovascular Aortic Repair

February 23, 2021 — Medtronic has voluntarily issued a global recall of unused Medtronic Valiant Navion thoracic stent ...

Home February 23, 2021
Home
News | Endovascular Aortic Repair

January 31, 2020 – The Society for Vascular Surgery (SVS) and Society of Thoracic Surgeons (STS) released new reporting ...

Home January 31, 2020
Home
News | Endovascular Aortic Repair

January 29, 2020 – The presence of a blood clot on the wall of the aorta in people with abdominal aortic aneurysms (AAA) ...

Home January 29, 2020
Home
Subscribe Now